Glaukos Corporation (NYSE:GKOS) CFO Joseph E. Gilliam purchased 2,100 shares of the company’s stock in a transaction on Wednesday, November 22nd. The stock was acquired at an average cost of $23.84 per share, for a total transaction of $50,064.00. Following the completion of the transaction, the chief financial officer now owns 102,100 shares in the company, valued at $2,434,064. The purchase was disclosed in a filing with the SEC, which is available at the SEC website.
Shares of Glaukos Corporation (GKOS) opened at $25.53 on Thursday. Glaukos Corporation has a twelve month low of $23.44 and a twelve month high of $52.49. The firm has a market capitalization of $883.15, a price-to-earnings ratio of 212.92 and a beta of 1.02.
Glaukos (NYSE:GKOS) last released its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.04 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.02) by $0.06. The company had revenue of $40.41 million for the quarter, compared to the consensus estimate of $38.69 million. Glaukos had a positive return on equity of 3.50% and a negative net margin of 0.64%. Glaukos’s revenue for the quarter was up 36.6% on a year-over-year basis. During the same quarter last year, the business posted $0.03 EPS. equities research analysts predict that Glaukos Corporation will post -0.03 earnings per share for the current year.
Several analysts recently commented on GKOS shares. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $60.00 price target on shares of Glaukos in a research note on Tuesday, November 7th. BMO Capital Markets reduced their price objective on Glaukos from $45.00 to $40.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 8th. Stephens restated an “overweight” rating and set a $40.00 target price (down previously from $47.00) on shares of Glaukos in a research report on Monday, November 13th. BidaskClub upgraded Glaukos from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Zacks Investment Research upgraded Glaukos from a “sell” rating to a “hold” rating in a report on Monday, November 13th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Glaukos has a consensus rating of “Buy” and an average price target of $46.57.
Several hedge funds have recently bought and sold shares of GKOS. Ameritas Investment Partners Inc. increased its position in Glaukos by 93.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock valued at $104,000 after buying an additional 1,212 shares in the last quarter. Valeo Financial Advisors LLC acquired a new position in Glaukos during the 3rd quarter valued at about $111,000. BNP Paribas Arbitrage SA boosted its stake in Glaukos by 740.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,539 shares of the medical instruments supplier’s stock valued at $147,000 after purchasing an additional 3,118 shares during the last quarter. Quantbot Technologies LP boosted its stake in Glaukos by 291.3% during the 3rd quarter. Quantbot Technologies LP now owns 7,653 shares of the medical instruments supplier’s stock valued at $252,000 after purchasing an additional 5,697 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new position in Glaukos during the 2nd quarter valued at about $262,000. 99.23% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Insider Buying: Glaukos Corporation (NYSE:GKOS) CFO Buys 2,100 Shares of Stock” was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.thelincolnianonline.com/2017/12/07/glaukos-corporation-gkos-cfo-joseph-e-gilliam-acquires-2100-shares-updated.html.
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.